Your browser doesn't support javascript.
loading
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.
Andersson, Niklas Worm; Thiesson, Emilia Myrup; Baum, Ulrike; Pihlström, Nicklas; Starrfelt, Jostein; Faksová, Kristýna; Poukka, Eero; Lund, Lars Christian; Hansen, Christian Holm; Aakjær, Mia; Kjær, Jesper; Cohet, Catherine; Goossens, Mathijs; Andersen, Morten; Hallas, Jesper; Meijerink, Hinta; Ljung, Rickard; Hviid, Anders.
Afiliación
  • Andersson NW; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark nian@ssi.dk.
  • Thiesson EM; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Baum U; Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Pihlström N; Division of Licensing, Swedish Medical Products Agency, Uppsala, Sweden.
  • Starrfelt J; Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway.
  • Faksová K; Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Poukka E; Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Lund LC; Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Hansen CH; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
  • Aakjær M; Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
  • Kjær J; Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  • Cohet C; Data Analytics Center, Danish Medicines Agency, Copenhagen, Denmark.
  • Goossens M; European Medicines Agency, Amsterdam, Netherlands.
  • Andersen M; European Medicines Agency, Amsterdam, Netherlands.
  • Hallas J; Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  • Meijerink H; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
  • Ljung R; Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
  • Hviid A; Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
BMJ ; 382: e074325, 2023 07 24.
Article en En | MEDLINE | ID: mdl-37487623
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Humans País/Región como asunto: Europa Idioma: En Revista: BMJ Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Humans País/Región como asunto: Europa Idioma: En Revista: BMJ Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca